RT Journal Article
SR Electronic
T1 SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease
JF Evidence Based Medicine
JO Evid Based Med
FD BMJ Publishing Group Ltd
SP 69
OP 70
DO 10.1136/ebmed-2016-110565
VO 22
IS 2
A1 Scheen, André J
YR 2017
UL http://ebm.bmj.com/content/22/2/69.abstract
AB